YAP1 and non-small cell lung carcinoma: Previous studies found that in patients with NSCLC harboring ALK rearrangement, high expression levels of YAP promoted resistance to ALK-TKIs, and the anti-tumor effect of ALK-TKIs was restored after YAP1 knockdown by siRNA in vivo and in vitro [97].